PL2768524T3 - Immunoterapia oparta na pd-l1 - Google Patents
Immunoterapia oparta na pd-l1Info
- Publication number
- PL2768524T3 PL2768524T3 PL12780408.6T PL12780408T PL2768524T3 PL 2768524 T3 PL2768524 T3 PL 2768524T3 PL 12780408 T PL12780408 T PL 12780408T PL 2768524 T3 PL2768524 T3 PL 2768524T3
- Authority
- PL
- Poland
- Prior art keywords
- based immunotherapy
- immunotherapy
- Prior art date
Links
- 238000009169 immunotherapy Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201170574 | 2011-10-17 | ||
| PCT/DK2012/050386 WO2013056716A1 (en) | 2011-10-17 | 2012-10-17 | Pd-l1 based immunotherapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2768524T3 true PL2768524T3 (pl) | 2022-09-19 |
Family
ID=47115103
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12780408.6T PL2768524T3 (pl) | 2011-10-17 | 2012-10-17 | Immunoterapia oparta na pd-l1 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9669078B2 (enExample) |
| EP (2) | EP2768524B1 (enExample) |
| JP (1) | JP6259763B2 (enExample) |
| CN (2) | CN113444165A (enExample) |
| BR (1) | BR112014009526B8 (enExample) |
| CA (1) | CA2850245C (enExample) |
| CY (1) | CY1125453T1 (enExample) |
| DK (1) | DK2768524T3 (enExample) |
| ES (1) | ES2918580T3 (enExample) |
| HR (1) | HRP20220924T1 (enExample) |
| HU (1) | HUE059406T2 (enExample) |
| LT (1) | LT2768524T (enExample) |
| PL (1) | PL2768524T3 (enExample) |
| PT (1) | PT2768524T (enExample) |
| SI (1) | SI2768524T1 (enExample) |
| WO (1) | WO2013056716A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6259763B2 (ja) * | 2011-10-17 | 2018-01-10 | ヘルレフ ホスピタルＨｅｒｌｅｖ Ｈｏｓｐｉｔａｌ | Ｐｄ−ｌ１に基づく免疫療法 |
| TWI676636B (zh) * | 2013-07-12 | 2019-11-11 | Ｖｌｐ醫療股份有限公司 | 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子 |
| WO2015153969A1 (en) | 2014-04-04 | 2015-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand discovery for t cell receptors |
| EP3936145A1 (en) * | 2014-07-31 | 2022-01-12 | The University Of Western Australia | A method for the identification of immunotherapy-drug combinations using a network approach |
| JP6918333B2 (ja) * | 2014-09-17 | 2021-08-11 | 学校法人近畿大学 | 細胞性免疫に認識されるペプチド、及びそれを利用した医薬薬剤 |
| LT3193917T (lt) | 2014-09-17 | 2021-11-25 | Io Biotech Aps | Vakcinų kompozicijos, apimančios triptofan-2,3-dioksigenazę arba jos fragmentus |
| KR20170072244A (ko) | 2014-10-10 | 2017-06-26 | 이데라 파마슈티칼즈, 인코포레이티드 | 관문 억제제를 가지는 tlr9 효능제를 이용한 암 치료 |
| KR20170083563A (ko) * | 2014-11-14 | 2017-07-18 | 리퀴드 제노믹스, 아이엔씨. | 암 진단 및/또는 모니터링을 위한 무세포 rna의 사용 방법 |
| JP6535133B2 (ja) * | 2015-05-15 | 2019-06-26 | リーバー ジェネティクス シーオー．， エルティーディー．Ｒｅｂｅｒ Ｇｅｎｅｔｉｃｓ Ｃｏ．， Ｌｔｄ． | 新規のバキュロウイルスベクター及び使用の方法 |
| KR102866196B1 (ko) | 2015-09-02 | 2025-09-29 | 알닐람 파마슈티칼스 인코포레이티드 | 프로그램된 세포사 1 리간드 1 (PD-L1) iRNA 조성물 및 그의 사용 방법 |
| EP3349785A1 (en) | 2015-09-16 | 2018-07-25 | Herlev Hospital | Vaccine compositions comprising c-c motif chemokine 22 (ccl22) or fragments thereof |
| LT3423087T (lt) | 2016-03-04 | 2024-01-25 | Io Biotech Aps | Kompleksinė priešvėžinė terapija |
| RU2747822C2 (ru) * | 2016-03-14 | 2021-05-14 | Ф. Хоффманн-Ля Рош Аг | Олигонуклеотиды для понижения экспрессии pd-l1 |
| AU2017234163B2 (en) | 2016-03-15 | 2023-01-19 | Mersana Therapeutics, Inc. | NaPi2b-targeted antibody-drug conjugates and methods of use thereof |
| CA3026572A1 (en) | 2016-06-10 | 2017-12-14 | Io Biotech Aps | Calr and jak2 vaccine compositions |
| JP7267014B2 (ja) * | 2016-06-21 | 2023-05-01 | アイオー バイオテック エーピーエス | 癌ワクチンにおける使用のためのｐｄｌ１ペプチド |
| RU2021127872A (ru) | 2016-06-30 | 2021-11-09 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
| US11135307B2 (en) | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| WO2018140890A1 (en) * | 2017-01-29 | 2018-08-02 | Zequn Tang | Methods of immune modulation against foreign and/or auto antigens |
| CN108503691B (zh) * | 2017-02-25 | 2021-07-23 | 复旦大学 | 一种人pd-l1蛋白高亲和性肽及其应用 |
| TW201834697A (zh) | 2017-02-28 | 2018-10-01 | 美商梅爾莎納醫療公司 | Her2標靶抗體－藥物結合物之組合療法 |
| CA3056807A1 (en) * | 2017-03-17 | 2018-09-20 | Vaximm Ag | Novel pd-l1 targeting dna vaccine for cancer immunotherapy |
| CN111372656A (zh) * | 2017-11-24 | 2020-07-03 | Io生物技术公司 | 抗体依赖性细胞介导的细胞毒性(adcc)的增强 |
| EP3717021A1 (en) | 2017-11-27 | 2020-10-07 | Mersana Therapeutics, Inc. | Pyrrolobenzodiazepine antibody conjugates |
| CN111757757A (zh) | 2017-12-21 | 2020-10-09 | 梅尔莎纳医疗公司 | 吡咯并苯并二氮呯抗体共轭物 |
| EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| FR3086534B1 (fr) * | 2018-10-01 | 2020-11-06 | Univ Bordeaux | Methode pour traiter une infection par le virus de l'immunodeficience humaine |
| CN113365664A (zh) | 2018-10-29 | 2021-09-07 | 梅尔莎纳医疗公司 | 具有含肽接头的半胱氨酸工程化的抗体-药物缀合物 |
| CN109593135B (zh) * | 2018-12-29 | 2021-01-15 | 百奥赛图江苏基因生物技术有限公司 | 抗人pd-l1单克隆抗体及其应用 |
| WO2020181402A1 (zh) * | 2019-03-10 | 2020-09-17 | 胡西木 | 一种抗肿瘤多肽及其应用 |
| CN113249447A (zh) * | 2019-04-26 | 2021-08-13 | 嘉兴允英医学检验有限公司 | 一种pd-l1表达水平检测的方法和试剂盒 |
| EP4031174A4 (en) * | 2019-09-17 | 2023-09-13 | Ohio State Innovation Foundation | Human anti-pd-l1 peptide vaccines and methods of their use |
| WO2021208106A1 (zh) * | 2020-04-18 | 2021-10-21 | 北京泽勤生物医药有限公司 | 一种治疗自身免疫病的融合肽 |
| CU24705B1 (es) * | 2020-10-22 | 2024-06-11 | Ct Ingenieria Genetica Biotecnologia | Antígeno quimérico que comprende el dominio extracelular de pd-l1 |
| GB202103673D0 (en) | 2021-03-17 | 2021-04-28 | Io Biotech Aps | Combination therapy for cancer |
| WO2022245841A1 (en) * | 2021-05-17 | 2022-11-24 | Wisconsin Alumni Research Foundation | Synthetic protein for inducing immune tolerance |
| KR102421307B1 (ko) * | 2021-11-19 | 2022-07-14 | 을지대학교 산학협력단 | 암 발생 및 성장 억제를 위한 신규 항암 백신 조성물 및 그를 이용한 백신화 방법 |
| JP2025508467A (ja) | 2022-02-24 | 2025-03-26 | アイオー バイオテック エーピーエス | 癌治療のヌクレオチド送達 |
| CN114702569B (zh) * | 2022-05-25 | 2023-01-10 | 深圳吉诺因生物科技有限公司 | Pd-l1相关疫苗及其应用 |
| WO2025043075A1 (en) * | 2023-08-24 | 2025-02-27 | The Johns Hopkins University | Methods of treating myocardial infarction, ischemia, and ischemia reperfusion injury |
| EP4527849A1 (en) | 2023-09-19 | 2025-03-26 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Hla-independent antigen binders, such as t-cell receptors, against pd-l1 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US58767A (en) | 1866-10-16 | John brougjbton | ||
| US5554372A (en) | 1986-09-22 | 1996-09-10 | Emory University | Methods and vaccines comprising surface-active copolymers |
| US6096313A (en) | 1996-02-09 | 2000-08-01 | Ludwig Institute For Cancer Research | Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant |
| EP1230360A4 (en) * | 1999-11-09 | 2003-04-02 | Human Genome Sciences Inc | 15 HUMAN SECRETED PROTEINS |
| CA2442066C (en) * | 2001-04-02 | 2005-11-01 | Wyeth | Pd-1, a receptor for b7-4, and uses therefor |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| ATE481985T1 (de) * | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | Immunpotenzierende zusammensetzungen |
| CA2508660C (en) * | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
| WO2008085562A2 (en) * | 2006-09-20 | 2008-07-17 | The Johns Hopkins University | Combinatorieal therapy of cancer and infectious diseases with anti-b7-h1 antibodies |
| WO2009026472A1 (en) * | 2007-08-21 | 2009-02-26 | The General Hospital Corporation | Methods for inducing tolerance |
| EP2662383A1 (en) * | 2008-08-25 | 2013-11-13 | Amplimmune, Inc. | PD-I antagonists and methods for treating infectious disease |
| US20130017199A1 (en) * | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| EP3798237A1 (en) * | 2010-03-05 | 2021-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| JP6259763B2 (ja) * | 2011-10-17 | 2018-01-10 | ヘルレフ ホスピタルＨｅｒｌｅｖ Ｈｏｓｐｉｔａｌ | Ｐｄ−ｌ１に基づく免疫療法 |
-
2012
- 2012-10-17 JP JP2014536116A patent/JP6259763B2/ja active Active
- 2012-10-17 CN CN202110437930.3A patent/CN113444165A/zh active Pending
- 2012-10-17 PT PT127804086T patent/PT2768524T/pt unknown
- 2012-10-17 US US14/352,407 patent/US9669078B2/en active Active
- 2012-10-17 BR BR112014009526A patent/BR112014009526B8/pt active IP Right Grant
- 2012-10-17 CA CA2850245A patent/CA2850245C/en active Active
- 2012-10-17 SI SI201232003T patent/SI2768524T1/sl unknown
- 2012-10-17 DK DK12780408.6T patent/DK2768524T3/da active
- 2012-10-17 PL PL12780408.6T patent/PL2768524T3/pl unknown
- 2012-10-17 EP EP12780408.6A patent/EP2768524B1/en active Active
- 2012-10-17 EP EP22163851.3A patent/EP4079319A1/en active Pending
- 2012-10-17 LT LTEPPCT/DK2012/050386T patent/LT2768524T/lt unknown
- 2012-10-17 ES ES12780408T patent/ES2918580T3/es active Active
- 2012-10-17 CN CN201280050948.7A patent/CN103917243B/zh active Active
- 2012-10-17 HR HRP20220924TT patent/HRP20220924T1/hr unknown
- 2012-10-17 HU HUE12780408A patent/HUE059406T2/hu unknown
- 2012-10-17 WO PCT/DK2012/050386 patent/WO2013056716A1/en not_active Ceased
-
2022
- 2022-08-02 CY CY20221100528T patent/CY1125453T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2768524T (pt) | 2022-07-05 |
| SI2768524T1 (sl) | 2022-09-30 |
| CN103917243A (zh) | 2014-07-09 |
| ES2918580T3 (es) | 2022-07-19 |
| WO2013056716A1 (en) | 2013-04-25 |
| CA2850245A1 (en) | 2013-04-25 |
| HUE059406T2 (hu) | 2022-11-28 |
| CY1125453T1 (el) | 2025-05-09 |
| US20140242101A1 (en) | 2014-08-28 |
| JP6259763B2 (ja) | 2018-01-10 |
| EP2768524A1 (en) | 2014-08-27 |
| HRP20220924T1 (hr) | 2022-10-28 |
| US9669078B2 (en) | 2017-06-06 |
| EP4079319A1 (en) | 2022-10-26 |
| BR112014009526A2 (pt) | 2017-05-09 |
| DK2768524T3 (da) | 2022-07-04 |
| EP2768524B1 (en) | 2022-05-04 |
| BR112014009526B8 (pt) | 2023-01-17 |
| CN113444165A (zh) | 2021-09-28 |
| BR112014009526B1 (pt) | 2021-07-13 |
| JP2014534202A (ja) | 2014-12-18 |
| LT2768524T (lt) | 2022-07-25 |
| CN103917243B (zh) | 2021-05-11 |
| CA2850245C (en) | 2020-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE059406T2 (hu) | PD-L1 alapú immunterápia | |
| DK3424953T3 (en) | Terapeutiske antistoffer | |
| DK2691417T4 (en) | Antistof fc-varianter | |
| PL3434695T3 (pl) | Ulepszona immunoterapia | |
| GB201103955D0 (en) | Antibodies | |
| GB201112056D0 (en) | Antibodies | |
| EP2755962A4 (en) | AZAINDAZOLES | |
| EP2754063A4 (en) | EXTENSIBILITY OF THE SMB2 PROTOCOL | |
| EP2723631A4 (en) | QUADFOILER | |
| EP2673635A4 (en) | IMMUNOTHERAPY THROUGH APOE | |
| EP2776444A4 (en) | dihydropteridinones | |
| AP2014007621A0 (en) | 2-Thiopyrimidinones | |
| GB201117538D0 (en) | Methods | |
| GB201120860D0 (en) | Cancer immunotherapy | |
| EP2695208A4 (en) | MICRO-THERMOCOUPLE | |
| GB201301300D0 (en) | No details | |
| GB201119167D0 (en) | Novel bachteriophages | |
| DK2770906T3 (en) | Applanationstonometer | |
| ZA201403228B (en) | Heterocyclypyri(mi)dinylpyrazole | |
| EP2714074A4 (en) | ANTIBODIES AGAINST EMR1 | |
| GB201100001D0 (en) | TidySqueeze2 | |
| AU5171P (en) | Sunparamiho Mandevilla xamabilis | |
| AU5026P (en) | Goldstrike Agapanthus inapertus | |
| GB201303586D0 (en) | No details | |
| GB201216278D0 (en) | No details |